Home/Pipeline/RlapsRisk® BC

RlapsRisk® BC

Early Breast Cancer

ApprovedCommercial

Key Facts

Indication
Early Breast Cancer
Phase
Approved
Status
Commercial
Company

About Owkin

Founded in 2016 by an oncologist and a machine learning pioneer, Owkin is building an agentic AI infrastructure for biology, aiming to automate R&D and connect research directly to patient care. Its core platform, K Pro, is an AI agent designed to generate and validate therapeutic hypotheses using real-world patient data. The company is well-funded, has commercialized CE-marked diagnostics, and collaborates with a vast network of academic and pharmaceutical partners to advance precision medicine.

View full company profile